My overall impression is they are focusing efforts on the indications that they believe they're really sure they're going to do well on and hope for some good market reaction to positive results next year which will set them up for a capital raise at a higher price than now. Once they have those they'll then focus on other indications.
To be fair the numbers are pretty mind-blowing on diabetic foot ulcer numbers in the US, let alone UTI's. Those two markets alone would be a company maker.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
29.0¢ |
Change
-0.005(1.69%) |
Mkt cap ! $85.06M | |||
| Open | High | Low | Value | Volume |
| 29.0¢ | 29.0¢ | 29.0¢ | $3.794K | 13.08K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2809 | 29.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 29.5¢ | 22819 | 3 |
View Market Depth
| Last trade - 10.15am 24/06/2025 (20 minute delay) ? |
| RCE (ASX) Chart |